News
-
-
-
PRESS RELEASE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Jaguar Health's crofelemer undergoing clinical studies for rare diseases SBS-IF and MVID in multiple regions; Orphan Drug Designation granted by FDA and EMA -
-
-
PRESS RELEASE
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
Jaguar Health announces Canalevia-CA1, a canine-specific crofelemer drug for chemotherapy-induced diarrhea in dogs with FDA approval, detailed safety information provided -
-
-
PRESS RELEASE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Inc. announces extension of conditional approval by FDA for Canalevia®-CA1 drug for chemotherapy-induced diarrhea in dogs and seeks partners for NP300 prescription drug for general diarrhea in dogs at Pet Connect conference -
